These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 12570705)

  • 1. Poly(ADP-ribose) polymerase inhibitors.
    Southan GJ; Szabó C
    Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
    Virág L; Szabó C
    Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
    Virág L
    Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
    Komjáti K; Besson VC; Szabó C
    Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
    Henning RJ; Bourgeois M; Harbison RD
    Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative mechanisms of inhibiting activity of poly (ADP-ribose) polymerase-1.
    Sriram CS; Jangra A; Bezbaruah BK; V AK; Sykam S
    Front Biosci (Schol Ed); 2016 Jan; 8(1):123-8. PubMed ID: 26709902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
    de la Lastra CA; Villegas I; Sánchez-Fidalgo S
    Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation.
    Erdélyi K; Bakondi E; Gergely P; Szabó C; Virág L
    Cell Mol Life Sci; 2005 Apr; 62(7-8):751-9. PubMed ID: 15868400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
    Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
    Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural inhibitors of poly(ADP-ribose) polymerase-1.
    Banasik M; Stedeford T; Strosznajder RP
    Mol Neurobiol; 2012 Aug; 46(1):55-63. PubMed ID: 22476980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
    Pacher P; Szabó C
    Cardiovasc Drug Rev; 2007; 25(3):235-60. PubMed ID: 17919258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy.
    Kuchmerovska T; Shymanskyy I; Donchenko G; Kuchmerovskyy M; Pakirbaieva L; Klimenko A
    J Diabetes Complications; 2004; 18(4):198-204. PubMed ID: 15207836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions.
    D'Amours D; Desnoyers S; D'Silva I; Poirier GG
    Biochem J; 1999 Sep; 342 ( Pt 2)(Pt 2):249-68. PubMed ID: 10455009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
    Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
    Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
    BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
    Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
    Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection.
    Skaper SD
    Ann N Y Acad Sci; 2003 May; 993():217-28; discussion 287-8. PubMed ID: 12853316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation.
    Aguilar-Quesada R; Muñoz-Gámez JA; Martín-Oliva D; Peralta-Leal A; Quiles-Pérez R; Rodríguez-Vargas JM; Ruiz de Almodóvar M; Conde C; Ruiz-Extremera A; Oliver FJ
    Curr Med Chem; 2007; 14(11):1179-87. PubMed ID: 17504138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
    Nguewa PA; Fuertes MA; Valladares B; Alonso C; Pérez JM
    Prog Biophys Mol Biol; 2005 May; 88(1):143-72. PubMed ID: 15561303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.